Reckitt slump offers a cue to slim down 18 Mar 2024 The $41 bln Lysol maker’s shares fell sharply after it lost a US court case. One option for Reckitt Benckiser is to separate the nutrition arm, focus of the legal woes. That would ease the hit to the rest of the group, but also leave a new arm that may yet be worth something.
Adidas catch-up remains off the necessary pace 13 Mar 2024 The $37 bln sneaker maker is emerging from its Yeezy trainer crisis. CEO Bjorn Gulden’s focus on fashionable trainers is helping to grow sales. But given the ropey economic outlook, which is hitting rival Nike, investors don’t yet look convinced he can deliver on his ambitions.
This year’s Oscar winner is…Ozempic 8 Mar 2024 The weight loss drug and its peer Mounjaro will make more than one red-carpet appearance at the Academy Awards. Such free advertising has long helped luxury firms like LVMH and Hermes sustain high pricing power, margins and valuations. Now drugmakers are in on the act.
Taylor Swift is Thai economy’s antihero 6 Mar 2024 Singapore's exclusive deal to host the pop star's Southeast Asia concerts has irked its neighbours. Thailand, with the slowest post-pandemic recovery, is upset at missing out on the spoils. Those are debatable and in any event wouldn't shake off the $500 bln economy's malaise.
Bayer’s inertia will make mounting problems worse 5 Mar 2024 The $30 bln seeds and drugs maker has ruled out a rapid breakup. Bayer could have used a consumer health sale to cut debt and offset bigger US litigation costs. Betting instead that it can grow its way out of trouble risks exacerbating a yawning discount to the sum of its parts.
Say hello again to the chief operating officer 4 Mar 2024 The role lost its mojo as growth, revenue and marketing execs muscled into C-suites. Roughly one in three big companies has a COO, down from nearly half in 2000. With money no longer cheap and profitability back in vogue, there’s a fresh case for hiring a solid second-in-command.
Cosmetics IPO application calls for a steady hand 4 Mar 2024 Buyout firm CVC is braving uncertain markets to list retailer Douglas, possibly for 7 bln euros. Shoppers’ appetite for premium makeup despite inflation is a positive sign. Yet the group’s high leverage and competition from Sephora call for a valuation discount to US rival Ulta.
Elliott has limited ammo in UK retail bidding war 4 Mar 2024 The US investment group’s latest $951 mln offer for retailer Currys could have yielded an adequate return. But the target has rejected it. Hiking the offer looks tricky given the ropey UK economy, reduced scope for leverage, and potential rival bidder JD.com’s deep pockets.
Stephen King ghost-writes trustbusting bestseller 27 Feb 2024 The US FTC is suing to block the $25 bln merger of grocers Kroger and Albertsons partly because of perceived harm to union labor. It resembles, oddly enough, a winning DOJ lawsuit over Penguin’s deal to buy Simon & Schuster. The case has a good shot at becoming a horror classic.
Alibaba is the ultimate contrarian China bet 21 Feb 2024 The $188 bln e-commerce group was once emblematic of the country’s growth and tech innovation. But over-expansion, regulatory crackdowns, and slowing consumption are forcing CEO Eddie Wu to perform a hard reset. Winning back investors requires Beijing to correct course too.
JD is logical winner of odd UK retail bidding war 19 Feb 2024 The $37 bln Chinese e-tailer is mulling an offer for Britain’s Currys, also the subject of interest from Elliott Advisors. A feeding frenzy for a sub-$1 bln UK asset with an unproven turnaround story sounds weird. But JD.com’s need to expand overseas is a strong motivation.
China offers more New Year red flags than packets 19 Feb 2024 A record number of Chinese travelled for the holiday, trips were up 19% from 2019, but they spent less per journey. Overseas travel remains subdued. Consumer tastes are changing but the low confidence fuelling deflation is evident. On that front, there is limited festival cheer.
DSM’s China de-risking plan hinges on booster shot 15 Feb 2024 Shares in the $30 bln Dutch firm surged 14% on plans to hive off its unit that makes vitamins for cattle. DSM is right to steer away from a business hurt by Chinese competition. But management needs it to recover to justify investors’ enthusiasm.
Heineken dilutes beer’s merrier future 14 Feb 2024 The $54 bln group’s higher prices led to lower volumes, at odds with Carlsberg’s cheerier numbers. Diageo reckons drinkers are shifting from spirits to beer, which should help brewers. Still, without clear evidence investors may not price in the growth a windfall should imply.
Capital Calls: Lyft 14 Feb 2024 Concise views on global finance: The US ride-hailing firm mistakenly forecast 500 basis points of margin improvement for 2024, causing its stock to surge some 60% before it came back to earth.
Hermès’ winning style is hard to replicate 9 Feb 2024 The French seller of $10,000 Birkin bags has outshined rivals, shrugging off inflation fears and a slowing China. Elite shoppers who see its high-end leather products as a store of value create resilience. Gucci-like brands, more exposed to fashion moods, look more fragile.
UK $13 bln cardboard saga has durable M&A endgame 9 Feb 2024 Three years after its last approach, $7.4 bln Mondi wants to merge with $5.4 bln DS Smith. Amid slowing consumer demand, there’s more strategic and financial logic in uniting the UK-listed packagers. That doesn’t mean there won’t be a squabble over how they’re scrunched together.
Hyundai’s India IPO will crush Korean discount 9 Feb 2024 A Mumbai listing of its local unit at a $30 bln valuation would secure an earnings multiple many times its parent. Proceeds will fuel blistering growth and enable Hyundai to cut more deals. It rarely makes sense to float subsidiaries but this plan looks more than roadworthy.
The obesity drug craze is entering its next phase 8 Feb 2024 Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world.
Toyota hitches a ride with the zeitgeist 7 Feb 2024 The car company’s bet on a slower transition is playing well. Shares hit a record high as third-quarter earnings grew 86% and sales of hybrids rose nearly 50%. Even a slowdown in China didn’t dampen the mood as expectations for the world’s largest auto market are fast fading.